Β-Cyclodextrin

• CAS: 7585-39-9
• Catalog Number: ACM7585399
• Category: Inhibitors
• Molecular Weight: 1134.98
• Molecular Formula: C42H70O35
• Description: DryPowder, Liquid; Liquid;Virtually odourless white or almost white crystalline solid
• IUPAC Name: (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
• Canonical SMILES: C(C1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(O2)C(C8O)O)CO)CO)CO)CO)CO)CO)O)O)O
• InChI: InChI=1S/C42H70O35/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51/h8-63H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m1/s1
• InChI Key: WHGYBXFWUBPSRW-FOUAGVGXSA-N
• Solubility: Sparingly soluble in water; freely soluble in hot water; slightly soluble in ethanol
• Appearance: Solid
• Application: Β-Cyclodextrin serves as a versatile cyclodextrin commonly used across pharmaceutical, food, and chemical industries due to its ability to form inclusion complexes. This cyclic oligosaccharide is produced naturally from starch through enzymatic conversion and features seven alpha-(1->4) linked D-glucopyranose units. Its unique molecular structure, characterized by a hydrophobic internal cavity and a hydrophilic external surface, allows it to effectively encapsulate various guest molecules. In pharmaceuticals, β-cyclodextrin is primarily employed to enhance the solubility and bioavailability of poorly soluble drugs, mitigate gastrointestinal irritation, and prevent undesirable interactions between drugs and excipients. While being affordable and widely available, it is noteworthy that β-cyclodextrin exhibits nephrotoxicity and should not be used in parenteral formulations. Additionally, it is utilized to mask unpleasant tastes and stabilize formulations in oral tablet and capsule preparations. Beyond pharmaceuticals, β-cyclodextrin finds applications in drug delivery, agriculture, environmental engineering, and the formulation of cosmetics and eye drops, where it enhances drug solubility and stability, reducing irritation and facilitating better absorption.
• Storage: Powder-20°C, 3 years; 4°C, 2 years; In solvent-80°C, 6 months; -20°C, 1 month.
• Complexity: 1480
• Covalently-Bonded Unit Count: 1
• EC Number: 231-493-2;231-493-2
• Exact Mass: 1134.369764g/mol
• Formal Charge: 0
• H-Bond Acceptor: 35
• H-Bond Donor: 21
• Heavy Atom Count: 77
• Monoisotopic Mass: 1134.369764g/mol
• Rotatable Bond Count: 7
• Shipping: Can be shipped at room temperature, where not in use may vary.
• Source: Bacillus
• UNII: JV039JZZ3A
• XLogP3: -15

Synthetic Use

Upstream Synthesis Route 1

• 1178862-93-5

• 21967-41-9
• 7585-39-9

Reference: [1] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2009, vol. 73, # 4, p. 752 - 756

Upstream Synthesis Route 2

• 98169-85-8

• 29390-67-8
• 7585-39-9

Reference: [1]Tetrahedron Letters,1993,vol. 34,p. 2457 - 2460

Downstream Synthesis Route 1

• 7585-39-9

• 1109-28-0
• 50-99-7
• 34612-38-9
• 34620-76-3
• 34620-77-4
• 69-79-4

Reference: [1] Carbohydrate Research, 2012, vol. 360, p. 93 - 101,9
[2] Carbohydrate Research, 2012, vol. 360, p. 93 - 101

Downstream Synthesis Route 2

• 91-64-5
• 7585-39-9

• 495-78-3
• 1481-92-1
• 14864-24-5

Reference: [1]Analytical Chemistry,1989,vol. 61,p. 905 - 909

Downstream Synthesis Route 3

• 2232-08-8
• 7585-39-9

• 84216-71-7

Reference: [1]Tetrahedron,1994,vol. 50,p. 12979 - 12988

* For details of the synthesis route, please refer to the original source to ensure accuracy.